EHang Files Annual Report on Form 20-F for Fiscal Year 2023
GUANGZHOU, China, April 15, 2024 (GLOBE NEWSWIRE) — EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading […]
CVRx announces availability of additional data supporting long-term benefits of Barostim
BeAT-HF trial data published in the European Journal of Heart Failure and new abstracts presented at THT conference MINNEAPOLIS, Minn., […]
Hillman Sets First Quarter 2024 Earnings Release and Results Presentation Date
CINCINNATI, April 15, 2024 (GLOBE NEWSWIRE) — Hillman Solutions Corp. (Nasdaq: HLMN) (“Hillman”), a leading provider of hardware products and […]
Venus Concept to Release First Quarter of Fiscal Year 2024 Financial Results on May 15, 2024
TORONTO, April 15, 2024 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical […]
Telos Corporation, an Official TSA PreCheck® Enrollment Provider, Expands Enrollment and Renewal Options by Opening New Locations
ASHBURN, Va., April 15, 2024 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), an authorized enrollment provider, continues to expand locations […]
Banle Energy International Limited Supports Yang Ming’s inaugural B24 Biofuel Bunkering Services in Yantian, Shenzhen
HONG KONG, April 15, 2024 (GLOBE NEWSWIRE) — On April 14, 2024, Banle Energy International Limited, a subsidiary of the […]
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline […]
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Expansion Cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation Cohorts data at Day 170 […]
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
New Gene Expression Analysis from Ongoing Phase 2 Study Provides Strong Biomarker Evidence that Treatment with TFF TAC Results in […]
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s […]
